Abstract

ABSTRACT Introduction: Acute promyelocytic leukemia (APL) is caused by t(15;17)(q24;q21) translocation, which product is the fusion oncoprotein PML-RARa (promyelocytic leukemia-retinoic acid receptor alpha). The morphology of leukemic promyelocytes is usually characteristic, with the presence of faggot cells and coarse cytoplasmic granulations; immunophenotype is characteristic in most cases. However, definitive laboratory diagnosis should be performed by detecting t(15;17) or by PML-RARa fusion protein. Objectives: To compare cytomorphology, flow cytometry, and classical cytogenetic of bone marrow samples from patients with APL, treated at the Complexo Hospital de Clinicas da Universidade Federal do Parana (CHC-UFPR), as well as describe the possible discrepancies between the methodologies. Method: Retrospective analysis of APL cases treated at the CHC-UFPR from January 2000 to July 2018. Results: Eighty-eight patients (42 man/ 46 woman; mean age: 34 years), 42.1% of them presented a high-risk prognosis. Flow cytometry was performed in 83 cases (94.3%); karyotype was performed in 79 cases (89.7%), but translocation t(15;17) was confirmed in only 53 cases (60.2%). From the 28 patients with a non-conclusive karyotype; fourteen (15.9%) of them presented the PML-RARa transcript in the molecular analysis. In total, 35 patients (39 8%) performed research of the PML-RARa gene by molecular biology. Only 45 patients (51.1%) presented concordant diagnosis among the three technical exams (morphology, flow cytometry and cytogenetics). Overall survival was 67% at 4.8 years, with 29 deaths. Conclusion: Genetic confirmation was observed in 76.1% of samples, 60.2% by conventional cytogenetics and 15.9% by molecular biology. There was a disagreement between the methodologies, and a low sensibility of the conventional cytogenetics, demonstrating the importance of performing molecular techniques for diagnostic confirmation.

Highlights

  • Acute promyelocytic leukemia (APL) is caused by t(15;17)(q24;q21) translocation, which product is the fusion oncoprotein PML-RARa

  • The APL is characterized by the presence of the translocation t(15;17)(q22; q21)(2), which results in the breakage and fusion of the promyelocytic leukemia (PML) gene, located on chromosome 15, with retinoic acid receptor alpha (RARα) located on chromosome 17

  • This study aims to compare the results obtained in bone marrow morphological analysis, immunophenotype by flow cytometry and conventional cytogenetics from APL patients treated at Complexo Hospital de Clínicas da Universidade Federal do Paraná (CHC-UFPR)

Read more

Summary

Introduction

Acute promyelocytic leukemia (APL) is caused by t(15;17)(q24;q21) translocation, which product is the fusion oncoprotein PML-RARa (promyelocytic leukemia-retinoic acid receptor alpha). From the 28 patients with a non-conclusive karyotype; fourteen (15.9%) of them presented the PML-RARα transcript in the molecular analysis. The APL is characterized by the presence of the translocation t(15;17)(q22; q21)(2), which results in the breakage and fusion of the promyelocytic leukemia (PML) gene, located on chromosome 15, with retinoic acid receptor alpha (RARα) located on chromosome 17. The final product of the translocation is the fusion of the genes encoding the hybrid proteins PML-RARα and RARα-PML(3), oncoproteins with sensitivity to retinoid action(4). This oncoprotein causes interruption of maturation and the accumulation of cells in the stage of abnormal promyelocytes in the bone marrow(5). The nucleus is bilobed and the cytoplasm presents few or no granule(7)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call